Article
STING activation promotes robust immune response and NK cell-mediated tumor regression in…
medRxiv · 2022 · Berger, G.; Knelson, E. H.; Jimenez-Macias, J. L.; Nowicki, M. O.; Han, S.; Lizotte, P. H.; Adu-Berchie, K.; Stafford, A.; Dimitrikakis, N.; Chiocca, E. A.; Mooney, D. J.; Barbie, D. A.; Lawler, S. E.
Key facts
| Title | STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models |
|---|---|
| First author | Berger, G.; Knelson, E. H.; Jimenez-Macias, J. L.; Nowicki, M. O.; Han, S.; Lizotte, P. H.; Adu-Berchie, K.; Stafford, A.; Dimitrikakis, N.; Chiocca, E. A.; Mooney, D. J.; Barbie, D. A.; Lawler, S. E. |
| Journal | medRxiv |
| Published | Apr 24, 2022 |
| DOI | 10.1101/2022.02.28.481908 |
| Devices mentioned | BK110039, K062324, K121894, K810863 |
| Product codes mentioned | DBM, JJH, KIP, KIT, MVU, NJT, NSU, PFF, PFT, MHX, PCA, PCH |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1